Chinese Newspaper Coverage of (Unproven) Stem Cell Therapies and their Providers

Stem Cell Reviews and Reports

Volumn 9, Issue 2, 2013, Pages 111-118

  Ogbogu, Ubaka ^a   Du, Li ^a,c   Rachul, Christen ^b   Bélanger, Lisa ^a   Caulfield, Timothy ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CARLETON UNIVERSITY   (Canada)

^c WUHAN UNIVERSITY   (China)

Author keywords

Medical tourism; Public representations; Science communication; Stem cell therapies; Stem cell tourism; Stem cells; Unapproved stem cell treatments

Indexed keywords

EID: 84875600741     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-012-9425-0     Document Type: Article

References (69)

1. Lau, D., Ogbogu, U., Taylor, B., Stafinski, T., Menon, D., & Caulfield, T. (2008). Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell, 3(6), 591-594.
2. Regenberg, A. C., Hutchinson, L. A., Schanker, B., & Mathews, D. J. H. (2009). Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells, 27(9), 2312-2319.
3. Master, Z., & Ogbogu, U. (2012). Stem cell tourism in the era of personalized medicine: what we know, and what we need to know. Current Pharmacogenomics and Personalized Medicine, 10(2), 106-110.
4. Zarzeczny, A., Rachul, C., Nisbet, M., & Caulfield, T. (2010). Stem cell clinics in the news. Nature Biotechnology, 28(12), 1243-1246.
5. Levine, A. D., & Wolf, L. E. (2012). The roles and responsibilities of physicians in patients' decisions about unproven stem cell therapies. The Journal of Law, Medicine & Ethics, 40(1), 122-134.
6. Lindvall, O., & Hyun, I. (2009). Medical innovation versus stem cell tourism. Science, 324(5935), 1664-1665.
7. Kiatpongsan, S., & Sipp, D. (2009). Medicine. Monitoring and regulating offshore stem cell clinics. Science, 323(5921), 1564-1565.
8. Ryan, K. A., Sanders, A. N., Wang, D. D., & Levine, A. D. (2010). Tracking the rise of stem cell tourism. Regenerative Medicine, 5(1), 27-33.
9. McMahon, D. S., Thorsteinsdóttir, H., Singer, P. A., & Daar, A. S. (2010). Cultivating regenerative medicine innovation in China. Regenerative Medicine, 5(1), 35-44.
10. Song, P. (2011). The proliferation of stem cell therapies in post-Mao China: problematizing ethical regulation. New Genetics and Society, 30(2), 141-153.
11. Chen, H. (2009). Stem cell governance in China: from bench to bedside? New Genetics and Society, 28(3), 267-282.
12. Sipp, D. (2009). The rocky road to regulation. Nature reports stem cells [Internet]. Sep 23 [cited 2012 Nov 24]; Available from: http://www. nature. com/doifinder/10. 1038/stemcells. 2009.
13. McMahon, D. S., & Thorsteinsdóttir, H. (2010). Lost in translation: China's struggle to develop appropriate stem cell regulations. SCRIPTed, 7(2), 283-294.
14. Murdoch, C. E., & Scott, C. T. (2010). Stem cell tourism and the power of hope. The American Journal of Bioethics, 10(5), 16-23.
15. Qiu, J. (2008). Injection of hope through China's stem-cell therapies. Lancet Neurology, 7(2), 122-123.
16. Qiu, J. (2009). Trading on hope. Nature Biotechnology, 27(9), 790-792.
17. Chen, H., Gottweis, H. (2011). Stem cell treatments in China: rethinking the patient role in the global bio-economy. Bioethics, doi: 10. 1111/j. 1467-8519. 2011. 01929. x.
18. McMahon, D. S., & Thorsteinsdóttir, H. (2011). Making stem cells count for global health. Regenerative Medicine, 6(6s), 163-166.
19. Sipp, D. (2009). Stem cell research in Asia: a critical view. Journal of Cellular Biochemistry, 107(5), 853-856.
20. Salter, B., Cooper, M., & Dickins, A. (2006). China and the global stem cell bioeconomy: an emerging political strategy? Regenerative Medicine, 1(5), 671-683.
21. Yuan, W., Sipp, D., Wang, Z. Z., Deng, H., Pei, D., Zhou, Q., et al. (2012). Stem cell science on the rise in China. Cell Stem Cell, 10(1), 12-15.
22. (2010). Stem-cell laws in China fall short. Nature, 467(7316), 633.
23. Cyranoski, D. (2012). China's stem-cell rules go unheeded. Nature, 484(7393), 149-150.
24. Cyranoski, D. (2009). Stem-cell therapy faces more scrutiny in China. Nature, 459(7244), 146-147.
25. Caplan, A., & Levine, B. (2010). Hope, hype and help: ethically assessing the growing market in stem cell therapies. The American Journal of Bioethics, 10(5), 24-25.
26. Caulfield, T., & Zarzeczny, A. (2012). Stem cell tourism and Canadian family physicians. Can Fam Physician, 58(4), 365-368. e182-185.
27. MacReady, N. (2009). The murky ethics of stem-cell tourism. The Lancet Oncology, 10(4), 317-318.
28. Master, Z., & Resnik, D. B. (2011). Stem-cell tourism and scientific responsibility. Stem-cell researchers are in a unique position to curb the problem of stem-cell tourism. EMBO Reports, 12(10), 992-995.
29. Hyun, I., Lindvall, O., Ahrlund-Richter, L., Cattaneo, E., Cavazzana-Calvo, M., Cossu, G., et al. (2008). New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell, 3(6), 607-609.
30. Blight, A., Curt, A., Ditunno, J. F., Dobkin, B., Ellaway, P., Fawcett, J., et al. (2009). Position statement on the sale of unproven cellular therapies for spinal cord injury: the international campaign for cures of spinal cord injury paralysis. Spinal Cord, 47(9), 713-714.
31. Mitka, M. (2010). Troubled by "stem cell tourism" claims, group launches web-based guidance. JAMA: The Journal of the American Medical Association, 304(12), 1315-1316.
32. Zhu, D., Chen, L., & Hong, T. (2012). Position statement of the Chinese Diabetes Society regarding stem cell therapy for diabetes. Journal of Diabetes, 4(1), 18-21.
33. Australian Stem Cell Centre. Stem cell therapies: Now and in the future-the Australian Stem Cell Centre patient handbook. [Internet] [cited 2012 Nov 24]. Available from: http://www. msnz. org. nz/Document. Doc?id=23.
34. International Society for Stem Cell Research (2008). Patient handbook on stem cell therapies. [Internet]. December 3 [cited 2012 Nov 24]. Available from http://www. isscr. org/clinical_trans/pdfs/ISSCRPatientHandbook. pdf.
35. Consumer updates > FDA warns about stem cell claims [Internet] [cited 2012 Nov 24]. Available from: http://www. fda. gov/forconsumers/consumerupdates/ucm286155. htm.
36. Sheldon, T. (2006). Dutch clinic is ordered to stop giving stem cell therapy. BMJ, 333(7572), 770.
37. Sheldon, T. (2007). The Netherlands bans private stem cell therapy. BMJ, 334(7583), 12.
38. Vogel G. (2011). Authorities shut controversial German stem cell clinic. ScienceInsider [Internet]. [cited 2012 Nov 24]. Available from: http://news. sciencemag. org/scienceinsider/2011/05/authorities-shut-controversial-g. html.
39. Costa Rican stem cell treatment facility to close [Internet] (2010). Marketwire. [cited 2012 Nov 24]. Available from: http://www. marketwire. com/press-release/costa-rican-stem-cell-treatment-facility-to-close-1271585. htm.
40. Carroll, R. (2010). Costa Rican health ministry bans experimental stem cell treatment. The Guardian [Internet]. Jun 7 [cited 2012 Nov 24]; Available from: http://www. guardian. co. uk/world/2010/jun/07/costa-rica-stem-cell-treatment.
41. Mendick, R. (2012). Stem cell doctor forced to close his clinic after child's death is back in business. The Telegraph [Internet]. Apr 7 [cited 2012 Nov 24]; Available from: http://www. telegraph. co. uk/health/healthnews/9192216/Stem-cell-doctor-forced-to-close-his-clinic-after-childs-death-is-back-in-business. html.
42. Cyranoski, D. (2012). Patients seek stem-cell compensation [Internet]. Nature Newsblog. [cited 2012 Nov 24]. Available from: http://blogs. nature. com/news/2012/07/patients-seek-stem-cell-compensation. html.
43. Bubela, T., Li, M. D., Hafez, M., Bieber, M., & Atkins, H. (2012). Is belief larger than fact: expectations, optimism and reality for translational stem cell research. BMC Medicine, 10(1), 133.
44. Weissman, I. (2012). Stem cell therapies could change medicine... if they get the chance. Cell Stem Cell, 10(6), 663-665.
45. Ahrlund-Richter, L., De Luca, M., Marshak, D. R., Munsie, M., Veiga, A., & Rao, M. (2009). Isolation and production of cells suitable for human therapy: challenges ahead. Cell Stem Cell, 4(1), 20-26.
46. Nagy, A., & Quaggin, S. E. (2010). Stem cell therapy for the kidney: a cautionary tale. Journal of the American Society of Nephrology, 21(7), 1070-1072.
47. Bell, E., Wallace, T., Chouinard, I., Shevell, M., & Racine, E. (2011). Responding to requests of families for unproven interventions in neurodevelopmental disorders: Hyperbaric oxygen "treatment" and stem cell "therapy" in cerebral palsy. Developmental Disabilities Research Reviews, 17(1), 19-26.
48. Thirabanjasak, D., Tantiwongse, K., & Thorner, P. S. (2010). Angiomyeloproliferative lesions following autologous stem cell therapy. Journal of the American Society of Nephrology, 21(7), 1218-1222.
49. Amariglio, N., Hirshberg, A., Scheithauer, B. W., Cohen, Y., Loewenthal, R., Trakhtenbrot, L., et al. (2009). Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Medicine, 6(2), e1000029.
50. Cyranoski, D. (2010). Korean deaths spark inquiry. Nature, 468(7323), 485.
51. Song, P. (2010). Biotech pilgrims and the transnational quest for stem cell cures. Medical Anthropology, 29(4), 384-402.
52. Rachul, C. (2011). "What have I got to lose?": An analysis of stem cell therapy patients' blogs. Health Law Review, 20(1), 5-12.
53. Bubela, T., Nisbet, M. C., Borchelt, R., Brunger, F., Critchley, C., Einsiedel, E., et al. (2009). Science communication reconsidered. Nature Biotechnology, 27(6), 514-518.
54. Caulfield, T., & Rachul, C. (2011). Science spin: iPS cell research in the news. Clinical Pharmacology and Therapeutics, 89(5), 644-646.
55. Seale, C. (2003). Health and media: an overview. Sociology of Health & Illness, 25(6), 513-531.
56. Davidson, R., Hunt, K., & Kitzinger, J. (2003). "Radical blueprint for social change"? Media representations of New Labour's policies on public health. Sociology of Health & Illness, 25(6), 532-552.
57. Adams, A., Lomax, G., & Santarini, A. (2011). Social media & stem cell science: examining the discourse. Regenerative Medicine, 6(6 Suppl), 121-124.
58. Ries, N. M., Rachul, C., & Caulfield, T. (2011). Newspaper reporting on legislative and policy interventions to address obesity: United States, Canada, and the United Kingdom. Journal of Public Health Policy, 32(1), 73-90.
59. Petersen, A. (2002). Replicating our bodies, losing our selves: news media portrayals of human cloning in the wake of dolly. Body & Society, 8(4), 71-90.
60. Nisbet, M. C., & Mooney, C. (2007). Framing Science. Science, 316(5821), 56.
61. Caulfield, T. (2004). Biotechnology and the popular press: hype and the selling of science. Trends in Biotechnology, 22(7), 337-339.
62. Caulfield, T., & Condit, C. (2012). Science and the sources of hype. Public Health Genomics, 15(3-4), 209-217.
63. Nerlich, B., & Halliday, C. (2007). Avian flu: the creation of expectations in the interplay between science and the media. Sociology of Health & Illness, 29(1), 46-65.
64. Qinglian, H. (2004). Media control in China. China Rights Forum [Internet]. [cited 2012 Nov 24]. page 11-28. Available from: http://www. hrichina. org/sites/default/files/oldsite/fs/downloadables/pdf/downloadable-resources/a1_MediaControl1. 2004. pdf.
65. Winfield, B. H., & Peng, Z. (2005). Market or party controls?: Chinese media in transition. International Communication Gazette, 67(3), 255-270.
66. Nhan, V. L. (2008). Media in China: methods of state control. The Orator, 3, 36-50.
67. Kennedy, J. J. (2009). Maintaining popular support for the Chinese communist party: the influence of education and the state-controlled media. Political Studies, 57(3), 517-536.
68. Rachul, C. M., Ries, N. M., & Caulfield, T. (2011). Canadian newspaper coverage of the A/H1N1 vaccine program. Canadian Journal of Public Health, 102(3), 200-203.
69. Du, L., & Rachul, C. (2012). Chinese newspaper coverage of genetically modified organisms. BMC Public Health, 12, 326.